Design and synthesis of a potent macrocyclic 1,6-naphthyridine anti-human cytomegalovirus (HCMV) inhibitors.
A novel class of macrocyclic 1,6-napthyridines designed to adopt the presumed bioactive conformation of anti-HCMV acyclic 1,6-napthyridines are described. Both 14- and 15-membered macrocycles were shown to be highly potent against HCMV HSV-1 and HSV-2.
Falardeau
Guy
G
ViroChem Pharma Inc., 275 Armand-Frappier Blvd., Laval, Québec, Canada H7V 4A7. gfalardeau@virochempharma.com
Lachance
Hugo
H
St-Pierre
Annie
A
Yannopoulos
Constantin G
CG
Drouin
Marc
M
Bédard
Jean
J
Chan
Laval
L
D000998:Antiviral Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D003587:Cytomegalovirus / Q000187:drug effects*; D015195:Drug Design; D018259:Herpesvirus 1, Human / Q000187:drug effects; D018258:Herpesvirus 2, Human / Q000187:drug effects; D006801:Humans; D008956:Models, Chemical; D008958:Models, Molecular; D015394:Molecular Structure; D009287:Naphthyridines / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*
D000998:Antiviral Agents; D009287:Naphthyridines